January 13-14, 2021 | 9:00AM EST | 2:00PM UTC | 3:00PM CET*
*Program is in development and subject to change
The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.
Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.
COVID-19 has brought unprecedented society level attention on a truly global scale into antibody and vaccine science and technology. Billions of people are now aware of antibodies, therapeutic, protective and diagnostic and vaccine design, manufacturing and clinical trial design. On a medical level, COVID-19 has impacted every single country on the planet with currently 68 million confirmed infections and 1.5 million deaths. These numbers will continue to increase until natural immunity, improved therapeutic interventions, vaccines or a combination of all three succeed. Vaccines are a reality – clinical administration has started. Interventional antibodies are in late stage trials. This COVID event is simply the biggest medical and economic threat in modern history and antibody and vaccine science is at its core. This conference will bring together in an accessible on-line format key influencers and scientific advances from around the world and unite the scientific community in the first steps of defeating COVID-19.
Keystone is unable to host its “Antibodies as Drugs” meeting as planned in January 2021 but will be replaced in part in a smaller COVID focused on-line meeting called “Antibodies and Vaccines as Drugs for COVID-19”. The meeting will have two 2½ hour on-line sessions, timed to fit in with most major time zones, each comprised of nine x 10 minutes invited oral presentations. One session will have a dedicated therapeutic antibody focus the other will have a vaccine focus. An on-line poster session is planned. Join the meeting to find out the very latest about COVID-19 therapeutic developments.
Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD
Abstract Submission Passed
ePoster / SciTalk Submission: Passed
Financial Aid Application: Passed
*Please note, abstract submission is required
in order to submit an ePoster and/or Scitalk
Speaking at this eSymposia
Abcellera Biologics Inc., Canada
Humabs BioMed SA, Switzerland
Sarah Catherine Gilbert
University of Oxford, UK
David P. Humphreys
UCB Pharma, UK
Michael G. Ison
Northwestern/Celltrion, Inc., USA
Regeneron Pharmaceuticals Inc, USA
Paul F. McKay
Imperial College, UK
Albert Einstein College of Medicine and Montefiore Medical Center, USA
CureVac GmbH, Germany
Ghent University, Belgium
Janssen Vaccines & Prevention B.V., Netherlands
Trevor RF Smith
Molecular Partners, Switzerland
Neeltje van Doremalen
NIAID, National Institutes of Health, USA
Patrick C. Wilson
University of Chicago, USA
X. Sunney Xie
Peking University, China
Tsinghua University, China
Subscribe to receive updates to the program for this meeting.
Funding for this conference was made possible (in part) by Grant No. 1R13CA254450-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.
The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.
Explore all cancer-related meetings on the Keystone Symposia website.